NCT04952272

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To study the safety and clinical effects of intratumor injecting CpG-ODN and in situ release of tumor antigen by interventional ablation or drug-eluting beads to treat advanced solid tumors.

Detailed description

1. Percutaneous microwave ablation or intratumor injection of drug-eluting beads to destroy cancer cells to release tumor-specific antigens 2. Intratumor injection of type A/C CpG-ODN with or without infusion of CAR-T cells secreting scFv against OX40 3. Assessing side effects and therapeutic efficacy after the combined treatments

Conditions

• Lung Cancer
• Hepatocellular Carcinoma
• Solid Tumor

Interventions

Type	Name	Description
COMBINATION_PRODUCT	CpG-ODN	CAR-T cells secreting scFv against OX40

Timeline

• Start date: 2021-03-01
• Primary completion: 2029-06-30
• Completion: 2036-06-30
• First posted: 2021-07-07
• Last updated: 2024-06-26

Locations

1 site across 1 country: China